Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM6WSU2)

• Drug Name: Dermolastin Drug Info
• Synonyms: Dermolastin

Indication

Disease Entry	ICD 11	Status	REF
Atopic dermatitis	EA80	Discontinued in Phase 2	[1]

• Cross-matching ID:
  PubChem CID: 188403
  TTD Drug ID: DM6WSU2

Molecule-Related Drug Atlas

Drug(s) Targeting Tissue kallikrein (KLK2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Avoralstat	DM5YHU2	Hereditary angioedema	4A00.14	Phase 2/3	[3]
VDA-1102	DMAJ85O	Actinic keratosis	EK90.0	Phase 2	[4]
JNJ-69086420	DM6VR13	Prostate cancer	2C82.0	Phase 1	[5]
JNJ-78278343	DM27FAN	Prostate cancer	2C82.0	Phase 1	[6]
JNJ-75229414	DMV6XBC	Prostate cancer	2C82.0	Phase 1	[7]
DM-107	DMRYQVJ	Atopic dermatitis	EA80	Investigative	[8]
hK2p01 derivative KLK2 inhibitor	DME13RQ	Discovery agent	N.A.	Investigative	[9]

Drug(s) Targeting Cationic trypsinogen (PRSS1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bortezomib	DMNO38U	Leukemia		Approved	[10]
MELAGATRAN	DM4W8RE	N. A.	N. A.	Phase 3	[11]
Ulinastatin	DMIQCFG	Premature labour	JB00	Phase 3	[12]
Alpha-1 antitrypsin	DM5EFXZ	Coagulation defect	3B10.0	Phase 2	[13]
RWJ-56423	DM6BIHE	Asthma	CA23	Discontinued in Phase 1	[14]
Patamostat	DM6HBQJ	Hypotension	BA20-BA21	Terminated	[13]
BMY-44621	DM8R3N0	N. A.	N. A.	Terminated	[15]
Grassystatin a	DM1PWX2	Discovery agent	N.A.	Investigative	[16]
2-(2-Hydroxy-phenyl)-1H-indole-5-carboxamidine	DM3UMYD	Discovery agent	N.A.	Investigative	[17]
4-(4-Benzyloxy-3-methoxy-benzylamino)-benzamidine	DME3PUT	Discovery agent	N.A.	Investigative	[18]

Drug(s) Targeting Neutrophil elastase (NE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sivelestat sodium hydrate	DMOSJD0	Acute lung injury	NB32.3	Phase 4	[19]
Epigallocatechin gallate	DMCGWBJ	Hepatic fibrosis	DB93.0	Phase 3	[20]
Sivelestat	DM6BZCV	Crohn disease	DD70	Phase 3	[21]
Tiprelestat	DM1SB94	Myocardial infarction	BA41-BA43	Phase 2	[22]
AZD9668	DMB87M3	Bronchiectasis	CA24	Phase 2	[23]
L-694,458	DMA0DSJ	Cystic fibrosis	CA25	Phase 2	[24]
BAY 85-8501	DMCPUKG	Bronchiectasis	CA24	Phase 2	[25]
DX-890	DMBFZET	Acute lung injury	NB32.3	Phase 2	[19]
POL-6014	DM9B68S	Cystic fibrosis	CA25	Phase 1	[26]
AZD-9819	DMWYHXG	Chronic obstructive pulmonary disease	CA22	Phase 1	[27]

Drug(s) Targeting Cathepsin G (CTSG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
JNJ-10311795	DM7OTQS	Chronic obstructive pulmonary disease	CA22	Phase 2	[28]
Peptide analog 59	DMZAMNX	N. A.	N. A.	Patented	[29]
Peptide analog 61	DM45JMT	N. A.	N. A.	Patented	[29]
Peptide analog 55	DMVLP8H	N. A.	N. A.	Patented	[29]
Peptide analog 60	DMMSTNA	N. A.	N. A.	Patented	[29]
Peptide analog 70	DMN43Q5	N. A.	N. A.	Patented	[29]
Peptide analog 56	DMBCFJU	N. A.	N. A.	Patented	[29]
Peptide analog 57	DM6IQWE	N. A.	N. A.	Patented	[29]
Peptide analog 58	DM7X62M	N. A.	N. A.	Patented	[29]
Peptide analog 62	DM28NK0	N. A.	N. A.	Patented	[29]

Drug(s) Targeting Coagulation factor IIa (F2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Argatroban	DMFI46A	Thrombosis	DB61-GB90	Approved	[30]
Pyridoxal Phosphate	DMO2K0J	Malnutrition	5B50-5B71	Approved	[31]
Bivalirudin	DMECRX1	Thrombocytopenia	3B64	Approved	[32]
Ximelegatran	DMU8ANS	Myocardial infarction	BA41-BA43	Approved	[33]
Dabigatran	DMDI6R4	Stroke	8B20	Approved	[34]
Desirudin Recombinant	DM2BTFN	Coagulation defect	3B10.0	Approved	[35]
Human prothrombin complex concentrate	DMPHVQ1	Bleeding disorder	GA20-GA21	Approved	[36]
Lepirudin	DM1I3D5	Thrombocytopenia	3B64	Approved	[37]
Anisindione	DM2C48U	Coagulation defect	3B10.0	Approved	[38]
ATryn antithrombin	DM79Y2T	Multiple sclerosis	8A40	Approved	[39]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cathepsin G (CTSG)	TTQAJF1	CATG_HUMAN	Inhibitor	[2]
Cationic trypsinogen (PRSS1)	TT2WR1T	TRY1_HUMAN	Inhibitor	[2]
Coagulation factor IIa (F2)	TT6L509	THRB_HUMAN	Inhibitor	[2]
Neutrophil elastase (NE)	TTPLTSQ	ELNE_HUMAN	Inhibitor	[2]
Tissue kallikrein (KLK2)	TTJLNAW	KLK2_HUMAN	Inhibitor	[2]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018071)
• [2] Arriva-ProMetic recombinant alpha 1-antitrypsin (rAAT) moves into the clinic for dermatology applications. ProMetic Life Sciences. 2009.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Clinical pipeline report, company report or official report of Vidac Pharma.
• [5] ClinicalTrials.gov (NCT04644770) A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer. U.S. National Institutes of Health.
• [6] ClinicalTrials.gov (NCT04898634) A Phase 1 Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer. U.S.National Institutes of Health.
• [7] ClinicalTrials.gov (NCT05022849) A Phase 1, Dose Escalation Study of JNJ-75229414, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against KLK2 for Metastatic Castration-Resistant Prostate Cancer. U.S.National Institutes of Health.
• [8] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2372).
• [9] Novel peptide inhibitors of human kallikrein 2. J Biol Chem. 2006 May 5;281(18):12555-60.
• [10] Characterization of a class of peptide boronates with neutral P1 side chains as highly selective inhibitors of thrombin. J Med Chem. 1995 Apr 28;38(9):1511-22.
• [11] Orally active thrombin inhibitors. Part 1: optimization of the P1-moiety. Bioorg Med Chem Lett. 2006 May 15;16(10):2641-7.
• [12] Intravenous administration of ulinastatin (human urinary trypsin inhibitor) in severe sepsis: a multicenter randomized controlled study. Intensive Care Med. 2014 Jun;40(6):830-8.
• [13] US patent application no. 2012,0251,516, PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT.
• [14] Inhibitors of serine proteases as potential therapeutic agents: the road from thrombin to tryptase to cathepsin G. J Med Chem. 2004 Feb 12;47(4):769-87.
• [15] Design and synthesis of conformationally constrained arginal thrombin inhibitors, Bioorg. Med. Chem. Lett. 7(17):2205-2210 (1997).
• [16] Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation. J Med Chem. 2009 Sep 24;52(18):5732-47.
• [17] Development of serine protease inhibitors displaying a multicentered short (<2.3 A) hydrogen bond binding mode: inhibitors of urokinase-type plasmi... J Med Chem. 2001 Aug 16;44(17):2753-71.
• [18] Design of selective phenylglycine amide tissue factor/factor VIIa inhibitors. Bioorg Med Chem Lett. 2005 Feb 1;15(3):817-22.
• [19] Emerging therapies for treatment of acute lung injury and acute respiratory distress syndrome. Expert Opin Emerg Drugs. 2007 Sep;12(3):461-77.
• [20] Evaluation of human neutrophil elastase inhibitory effect of iridoid glycosides from Hedyotis diffusa. Bioorg Med Chem Lett. 2010 Jan 15;20(2):513-5.
• [21] Neutrophil elastase inhibitor (sivelestat) reduces the levels of inflammatory mediators by inhibiting NF-kB. Inflamm Res. 2009 Apr;58(4):198-203.
• [22] Company report (Proteo Biotech AG)
• [23] Clinical pipeline report, company report or official report of AstraZeneca (2009).
• [24] Neutrophil elastase inhibitors as treatment for COPD. Expert Opin Investig Drugs. 2002 Jul;11(7):965-80.
• [25] Freezing the Bioactive Conformation to Boost Potency: The Identification of BAY 5-8501, a Selective and Potent Inhibitor of Human Neutrophil Elastase for Pulmonary Diseases. ChemMedChem. 2015 Jul;10(7):1163-73.
• [26] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2358).
• [27] Lipid Peroxide-Mediated Oxidative Rearrangement of the Pyrazinone Carboxamide Core of Neutrophil Elastase Inhibitor AZD9819 in Blood Plasma Samples. Drug Metab Dispos. 2015 Oct;43(10):1441-9.
• [28] Discovery of potent, selective, orally active, nonpeptide inhibitors of human mast cell chymase. J Med Chem. 2007 Apr 19;50(8):1727-30.
• [29] Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58.
• [30] Studies on the different modes of action of the anticoagulant protease inhibitors DX-9065a and Argatroban. I. Effects on thrombin generation. J Biol Chem. 2002 Dec 27;277(52):50439-44.
• [31] New antithrombotic drugs (excluding plasminogen activators. Arch Mal Coeur Vaiss. 2001 Nov;94(11 Suppl):1225-32.
• [32] New anticoagulants. Am Heart J. 2001 Aug;142(2 Suppl):S3-8.
• [33] Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90.
• [34] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
• [35] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [36] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2362).
• [37] Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis. Kidney Int Suppl. 1999 Nov;(72):S46-50.
• [38] Anticoagulation with anisindione in a patient with a warfarin-induced skin eruption. Pharmacotherapy. 2003 Apr;23(4):533-6.
• [39] Antithrombin III Utilization in a Large Teaching Hospital. P T. 2013 December; 38(12): 764-767, 779.